Search Result

Results for "

histones H4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (7) Bcl-2 Family (1) Caspase (1) Discoidin Domain Receptor (1) DNA Methyltransferase (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) EGFR (1) Epigenetic Reader Domain (3) Fungal (1) HDAC (15) Histone Acetyltransferase (5) Histone Methyltransferase (8) HSV (1) IKZF Family (1) Microtubule/Tubulin (4) PARP (1) PI3K (1) PROTACs (1) Sirtuin (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (3)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Click Chemistry

Cat. No.	Nom du produit	Target	Áreas de investigación	Chemical Structure

HY-144315

CYD19 Snail/HDAC-IN-1	HDAC	Cancer
CYD19 is a potent Snail/HDAC dual target inhibitor. CYD19 displays potent inhibitory activity against HDAC1 with an IC₅₀ of 0.405 μM and potent inhibition against Snail with a K_d of 0.18 μM. CYD19 increases histone H4 acetylation in HCT-116 cells and decreases the expression of Snail protein to induce cell apoptosis .

HY-145550

Amredobresib BI894999	Epigenetic Reader Domain	Cancer
Amredobresib (BI894999) is an orally active BET inhibitor. Amredobresib inhibits the binding of BRD4-BD1 and BRD4-BD2 bromodomains to acetylated histones with IC₅₀ values of 5 nM and 41 nM, respectively. Amredobresib exhibits anticancer activity against acute myeloid leukemia (AML) and NUT cancer .

HY-156257

UNC9512 1 Publications Verification	DNA/RNA Synthesis	Cancer
UNC9512 is a selective 53BP1 inhibitor with an IC₅₀ of 0.46 μM, and a K_d values of 0.17 μM. UNC9512 binds 53BP1 and its tandem Tudor domain, disrupts histone H4 interaction, and inhibits 53BP1 activity. UNC9512 can be used as a probe for DNA damage repair and Gene editing .

HY-P1958

Histone H4 (2-21)	HSV	Infection
Histone H4 (2-21) is the core histones associated with chromatinization of herpes simplex virus 1 (HSV-1) genomes .

HY-117709

BRD6688	HDAC	Neurological Disease
BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model .

HY-116818

Crebinostat	HDAC	Neurological Disease
Crebinostat is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.7 nM, 1.0 nM, 2.0 nM and 9.3 nM for HDAC1, HDAC2, HDAC3 and HDAC6, respectively. Crebinostat potently induces acetylation of both histone H3 and histone H4 as well as enhances the expression of the cAMP response element-binding protein (CREB) target gene Egr1. Crebinostat increases the density of synapsin-1 punctae along dendrites in cultured neurons. Crebinostat can modulate chromatin-mediated neuroplasticity and exhibits enhanced memory in mice .

HY-130538

1-Naphthohydroxamic acid 2 Publications Verification	HDAC	Cancer
1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC₅₀ of 14 μM. 1-Naphthohydroxamic acid is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC₅₀ >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity .1-Naphthohydroxamic acid can induce tubulin acetylation .

HY-150249

GSK3735967 1 Publications Verification	DNA Methyltransferase	Cancer
GSK3735967 is an selective, reversible, non-nucleoside inhibitor of DNMT1 with an IC₅₀ value of 40 nM. GSK3735967 contains a planar dicyanopyridine core that can specifically embed DNMT1 bound hemimethylated CpG dinucleotides. GSK3735967 has three binding sites, one of which can bind to **histone H4K20me3** .

HY-125236

BET-IN-19	Epigenetic Reader Domain	Cancer
BET-IN-19 (Compound 146) is a BET inhibitor. BET-IN-19 inhibits hlL-6 mRNA transcription (IC₅₀ ≤0.3 uM), and c-myc activity in human AML MV4-11 cell (IC₅₀ ≤0.3 uM)。BET-IN-19 inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC₅₀ ≤0.3 uM) .

HY-112806

ST8155AA1	Drug-Linker Conjugates for ADC HDAC EGFR Microtubule/Tubulin	Cancer
ST8155AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor. ST8155AA1 induces α-tubulin, histone H3/H4 acetylation via direct enzymatic inhibition. ST8155AA1 recognizes and binds EGFR, undergoes internalization into EGFR-expressing tumor cells. ST8155AA1 inhibits cancer cell proliferation and exerts activity in mouse tumor models. ST8155AA1 can be used for the research of non-small cell lung cancer .

HY-P10570

[Nle20] H4 peptide (16−23)	Histone Methyltransferase	Cancer
[Nle20] H4 peptide (16−23) is a peptide with strong inhibitory activity against histone methyltransferase SETD8 (K_d=0.14 μM), which inhibits SETD8's methylation of histone H4 by competing with SETD8's substrate binding site. [Nle20] H4 peptide (16−23) can be used as a lead compound for anticancer therapy .

HY-P2228

Chlamydocin (purity≥70%)	HDAC Apoptosis	Cancer
Chlamydocin (purity≥70%), a fungal metabolite, is a highly potent HDAC inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin (purity≥70%) exhibits potent antiproliferative and anticancer activities. Chlamydocin (purity≥70%) induces apoptosis by activating caspase-3 .

HY-P2178

Dihydrochlamydocin analog-1	HDAC	Cancer
Dihydrochlamydocin analog-1 (compound 2) is a Chlamydocin (HY-115761) analogue that inhibits histone H4 peptide deacetylation with IC₅₀ of 30 nM .

HY-160461

LTK-14A	HDAC	Metabolic Disease
LTK-14A, a derivative of Garcinol (HY-107569), is a selective histone butyrylation inhibitor. LTK-14A does not affect acetylation. LTK-14A significantly inhibits the butyrylation of H4K5 and downregulated the expression of proadipogenic genes, thus culminating in abolished adipogenesis. LTK-14A can be used for the study of obesity .

HY-120137

CMP-5	Histone Methyltransferase	Cancer
CMP-5 is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation but leaving normal B cells unaffected .

HY-W013500

(1-Nitroethene-1,2-diyl)dibenzene alpha-Nitrostilbene; α-Nitrostilbene; NSC 385	Histone Methyltransferase	Others
(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) is an inhibitor of protein arginine methyltransferase 1 (PRMT1; IC₅₀=11 μM in histone H4 methylation assay). It also inhibits histone H4 methylation by PRMT8, but not histone H3.1 methylation by CARM1 or Set7/9, at concentrations of 10 and 100 μM.

HY-121512

SK-7041	HDAC Apoptosis	Cancer
SK-7041 is a HDAC inhibitor with the IC₅₀ of 172 nM. SK-7041 induces the hyperacetylation of histones H3 and H4 .SK-7041 inhibits tumor cell growth in vivo and in vitro, induces cell apoptosis, and arrests cell cycle at the G1 phase .

HY-162060

YPX-C-05	HDAC	Cardiovascular Disease
YPX-C-05 is a hydroxamic acid-based HDAC inhibitor. YPX-C-05 exerts significant vasodilatory effects. YPX-C-05 exhibits inhibitory effects on HDACs and increases histone H4 acetylation in endothelial cells. YPX-C-05 can be used for hypertension research .

HY-146351

HDAC-IN-38	HDAC	Neurological Disease
HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .

HY-175821

PRMT1-IN-3	Histone Methyltransferase Apoptosis	Cancer
PRMT1-IN-3 is a potent protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC₅₀ of 4.11 μM. PRMT1-IN-3 inhibits PRMT6 and PRMT8 with IC₅₀s of 23.3 and 30.1 μM. PRMT1-IN-3 suppresses asymmetric dimethylarginine (ADMA) levels and histone *H4R3me2a* modification in triple-negative breast cancer (TNBC) cells. PRMT1-IN-3 induces cell cycle arrest, apoptosis, and inhibits migration and colony formation in MDA-MB-231 cells. PRMT1-IN-3 acts as chemotherapeutic sensitizers for Paclitaxel (HY-B0015). PRMT1-IN-3 can be used for the study of TNBC .

HY-P11551

Histone H4 peptide	Histone Acetyltransferase	Cancer
Histone H4 peptide is a peptide that interacts with hNatD. Histone H4 peptide exhibits polar interactions with hNatD. Histone H4 peptide can be used in lung cancer research .

HY-123699

NCT-10b	HDAC Microtubule/Tubulin	Cancer
NCT-10b is a selective HDAC6 inhibitor. NCT-10b mediates preferential α-tubulin acetylation without major histone H4 acetylation.NCT-10b can be used for the research of multiple myeloma .

HY-156091

PI3Kα/HDAC6-IN-1	PI3K HDAC	Cancer
PI3Kα/HDAC6-IN-1 (compound 21j) is a dual PI3Kα/HDAC6 inhibitor with IC₅₀ of 2.9 and 26 nM, respectively. PI3Kα/HDAC6-IN-1 also inhibits AKT(Ser473) phosphorylation and induces the accumulation of acetylated α-tubulin without affecting acetylated histones H3 and H4. PI3Kα/HDAC6-IN-1 efficiently inhibits L-363 cell line (IC₅₀=0.17 μM) and has good anti-cancer activity .

HY-121009

CCT077791	Histone Acetyltransferase Microtubule/Tubulin	Cancer
CCT077791 is a PCAF (IC₅₀: 7.3 μM (FlashPlate); 2.2 μM (Filter assay)) and *p300 histone* acetyltransferase** inhibitor. CCT077791 reduces total acetylation of histones H3 and H4, levels of specific acetylated lysine marks, and acetylation of α-tubulin. CCT077791 can be used in the research of colorectal cancer .

HY-182275

PROTAC PRMT1 degrader-1	PROTACs Histone Methyltransferase	Cancer
PROTAC PRMT1 degrader-1 (compound 4) is a PRMT1 PROTAC degrader, with a DC₅₀ of 0.77 μM (MCF-7 cells). PROTAC PRMT1 degrader-1 recruits the CRBN E3 ubiquitin ligase to induce proteasome-dependent degradation of PRMT1; it also forms a ternary complex with PRMT1 and CRBN, promoting ubiquitination and subsequent proteasomal degradation of PRMT1. PROTAC PRMT1 degrader-1 reduces the level of asymmetric dimethylarginine in cancer cells, as well as the level of asymmetric dimethylation of arginine 3 on histone H4, while inhibiting the growth of various cancer cells. PROTAC PRMT1 degrader-1 can be used in the research of breast cancer and melanoma .

HY-116267

MHY219	HDAC Apoptosis PARP Bcl-2 Family Androgen Receptor	Cancer
MHY219 is a histone deacetylase (HDAC) inhibitor with an IC₅₀ of 0.276 μM. MHY219 inhibits total HDAC enzyme activity, increases histone H3 and H4 hyperacetylation. MHY219 induces cance cells phase arrest, apoptosis and inhibits proliferationin. MHY219 increases cleavage of PARP, Bax, cytochrome c levels, androgen receptor expression and decreases Bcl-2 expression. MHY219 can be used for the research of prostate cancer .

HY-113846A

CMP-5 dihydrochloride	Histone Methyltransferase	Cancer
CMP-5 dihydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 dihydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 dihydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected .

HY-113846

CMP-5 hydrochloride	Histone Methyltransferase	Cancer
CMP-5 hydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 hydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 hydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected .

HY-181843

HDAC-IN-99	HDAC Apoptosis Histone Acetyltransferase Microtubule/Tubulin Caspase	Cancer
HDAC-IN-99 is a histone deacetylase (HDAC) inhibitor with an IC₅₀ of 37.73 nM, and it exhibits potent inhibitory activity against HDAC1 (IC₅₀ = 48.09 nM), HDAC2 (IC₅₀ = 300.28 nM) and HDAC6 (IC₅₀ = 9.16 nM). HDAC-IN-99 exerts broad-spectrum antiproliferative activity in various cancer cell lines. HDAC-IN-99 induces S-phase cell cycle arrest and apoptosis in colon cancer cells, increases the acetylation levels of histone H3, histone H4 and α-tubulin, and upregulates the expression of p21 as well as the cleavage of caspase-3. HDAC-IN-99 displays antitumor activity in colon cancer xenograft models. HDAC-IN-99 can be used for the research of colon cancer .

HY-181957

KB528	Epigenetic Reader Domain Histone Acetyltransferase Apoptosis IKZF Family	Cancer
KB528 is a p300/CBP histone acetyltransferase (KAT) inhibitor with low nM IC₅₀ values against human p300 and CBP, and exhibits selectivity over other KAT family members. KB528 modulates the IRF4 transcriptional network, downregulates the expression of IRF4, MYC, CAV2 and IGLL5, and reduces the protein level of IKZF3. KB528 potently induces apoptosis in multiple myeloma cells. KB528 is applicable to research related to multiple myeloma .

HY-114510

PRMT/HKMT-IN-1	Discoidin Domain Receptor Histone Acetyltransferase Sirtuin Fungal Apoptosis	Infection Cancer
PRMT/HKMT-IN-1 is an epigenetic multi-target protein arginine methyltransferases (PRMTs) and histone lysine methyltransferases (HKMTs) inhibitor. PRMT/HKMT-IN-1 inhibits Aspergillus nidulans RmtA with an IC₅₀ of 29 μM. PRMT/HKMT-IN-1 inhibits human PRMT1, p300/CBP HAT, CARM1, SET7, SIRT1 and SIRT2. PRMT/HKMT-IN-1 inhibits methylation of histone H3K4, *H4R3, and H3R17* residues. CBP/p300-IN-23 induces apoptosis, arrests cell cycle in S phase, and triggers granulocytic differentiation in leukemia cells. PRMT/HKMT-IN-1 can be used for the research of leukemia .

HY-181849

MS2928	Histone Methyltransferase	Cancer
MS2928 is a selective SETD8 inhibitor with an IC₅₀ of 0.14 μM against SETD8 methyltransferase activity. MS2928 reduces cellular H4K20_me1 levels and inhibits proliferation of SETD8-overexpressing multiple myeloma cells. MS2928 inhibits tumor growth in xenograft mouse models of SETD8-overexpressing multiple myeloma. MS2928 can be used for the study of SETD8 biological functions and multiple myeloma .

Cat. No.	Nom du produit	Target	Research Area

HY-P1958

Histone H4 (2-21)	HSV	Infection
Histone H4 (2-21) is the core histones associated with chromatinization of herpes simplex virus 1 (HSV-1) genomes .

HY-P4614

*(Lys(Ac)5,8,12,16)-Histone* H4 (1-25)-Gly-Ser-Gly-Ser-Lys(biotinyl)**	Peptides	Others
(Lys(Ac)5,8,12,16)-Histone H4 (1-25)-Gly-Ser-Gly-Ser-Lys(biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10570

[Nle20] H4 peptide (16−23)	Histone Methyltransferase	Cancer
[Nle20] H4 peptide (16−23) is a peptide with strong inhibitory activity against histone methyltransferase SETD8 (K_d=0.14 μM), which inhibits SETD8's methylation of histone H4 by competing with SETD8's substrate binding site. [Nle20] H4 peptide (16−23) can be used as a lead compound for anticancer therapy .

HY-P2228

Chlamydocin (purity≥70%)	HDAC Apoptosis	Cancer
Chlamydocin (purity≥70%), a fungal metabolite, is a highly potent HDAC inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin (purity≥70%) exhibits potent antiproliferative and anticancer activities. Chlamydocin (purity≥70%) induces apoptosis by activating caspase-3 .

HY-P2178

Dihydrochlamydocin analog-1	HDAC	Cancer
Dihydrochlamydocin analog-1 (compound 2) is a Chlamydocin (HY-115761) analogue that inhibits histone H4 peptide deacetylation with IC₅₀ of 30 nM .

HY-P4616

*(Lys(Ac)12)-Histone* H4 (1-21)-Gly-Gly-Lys(biotinyl)**	Peptides	Others
(Lys(Ac)12)-Histone H4 (1-21)-Gly-Gly-Lys(biotinyl) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P11551

Histone H4 peptide	Histone Acetyltransferase	Cancer
Histone H4 peptide is a peptide that interacts with hNatD. Histone H4 peptide exhibits polar interactions with hNatD. Histone H4 peptide can be used in lung cancer research .

Cat. No.	Nom du produit	Target	Research Area	Image

HY-P990435

*Anti-Histone* H4 Antibody**	Inhibitory Antibodies	Inflammation/Immunology
Anti-Histone H4 Antibody is a CHO-expressed human antibody that targets Histone H4. Anti-Histone H4 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Histone H4 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Nom du produit		Classification

HY-181849

MS2928		Alkynes
MS2928 is a selective SETD8 inhibitor with an IC₅₀ of 0.14 μM against SETD8 methyltransferase activity. MS2928 reduces cellular H4K20_me1 levels and inhibits proliferation of SETD8-overexpressing multiple myeloma cells. MS2928 inhibits tumor growth in xenograft mouse models of SETD8-overexpressing multiple myeloma. MS2928 can be used for the study of SETD8 biological functions and multiple myeloma .

Demande en ligne

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Civilité			Country or Region *
Nom du demandeur *			Nom de l'organisation *
Department *
Adresse e-mail *			Nom du produit *
Cat. No.			Requested quantity *
Numéro de téléphone *
Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: